Skip to main content

GOLDMAN SACHS GROUP INC

Position in RLMD — Relmada Therapeutics, Inc.

CIK 886982 NEW YORK, NY

Position in RLMD

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$4,865,311
+$4,164,961 QoQ
Shares Held
699,039
+382.1% QoQ
Ownership
0.666%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
17 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in RLMD Over Time

Shares Held

Position Value (USD)

Derivatives in RLMD

reported options exposure · as of Mar 31, 2026
CallValue
$169,128
CallShares
24,300
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

GOLDMAN SACHS GROUP INC holds $10,293,152,367 across 364 Biotechnology names. RLMD ranks #181 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in RLMD

Export CSV
21 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $4,865,311 699,039
2026-03-31 $169,128 24,300
2025-12-31 $117,369 24,300
2025-12-31 $700,350 145,000
2025-03-31 $32,630 120,852
2024-03-31 $549,829 118,243
2023-09-30 $38,994 12,998
2023-06-30 $399,373 162,347
2023-03-31 $451,601 199,824
2022-12-31 $913,363 261,709
2022-09-30 $2,641,265 71,347
2022-06-30 $3,497,464 184,174
2022-03-31 $790,563 29,291
2021-12-31 $1,899,008 84,288
2021-09-30 $2,256,208 86,082
2021-06-30 $238,314 7,445
2021-06-30 $403,326 12,600
2021-03-31 $376,183 10,684
2021-03-31 $443,646 12,600
2020-12-31 $451,705 14,085
2020-03-31 $3,624,016 106,245